Nuo Therapeutics (AURX) 10-K 19 Apr 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Apr. 15, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0001091596
Entity Registrant Name	Nuo Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	000-28443
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-3011702
Entity Address, Address Line One	8285 El Rio, Suite 190
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77054
City Area Code	346
Local Phone Number	396-4770
Title of 12(g) Security	Common Stock, $0.0001 par value
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 35,900,000
Entity Common Stock, Shares Outstanding		44,241,516
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	Houston, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 928,681	$ 2,051,208
Restricted cash	0	55,000
Accounts receivable, net	250,703	92,320
Inventory, net	209,589	240,005
Prepaid expenses and other current assets	174,471	196,378
Total current assets	1,563,444	2,634,911
Property and equipment, net	45,082	53,165
Operating lease right of use assets	269,354	359,284
Total assets	1,877,880	3,047,360
Liabilities and Stockholders' Equity
Common stock; $0.0001 par value; 100,000,000 shares authorized; 44,241,516 and 41,799,016 shares issued and outstanding at December 31, 2023 and 2022, respectively	4,424	4,180
Additional paid-in capital	30,970,965	28,951,963
Accumulated deficit	(29,936,241)	(26,764,805)
Total stockholders' equity	1,039,148	2,191,338
Total liabilities and stockholders' equity	1,877,880	3,047,360
Current liabilities
Accounts payable	394,518	397,703
Accrued expenses	188,622	123,275
Current portion of operating lease liabilities	91,387	79,453
Total current liabilities	674,527	600,431
Non-current portion of operating lease liabilities	164,205	255,592
Total liabilities	838,732	856,022
Commitments and contingencies (Note 8)

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	44,241,516	41,799,016
Common stock, shares outstanding (in shares)	44,241,516	41,799,016

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Revenue	$ 608,525	$ 112,250
Revenue	608,525	112,250
Costs of sales	126,092	19,214
Gross profit	482,433	93,036
Operating expenses
Selling, general and administrative	3,650,707	3,413,630
Total operating expenses	3,650,707	3,413,630
Loss from operations	(3,168,274)	(3,320,594)
Other income (expense)
Interest expense, net	(3,162)	(2,103)
Gain on settlement of legacy accounts payable obligations	0	146,438
Other income	0	4,523
Loss before benefit for income taxes	(3,171,436)	(3,171,736)
Net loss	$ (3,171,436)	$ (3,171,736)
Net loss per share – basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)
Weighted average shares outstanding – basic and diluted (in shares)	42,077,811	40,001,089
Product [Member]
Revenue:
Revenue	$ 608,525	$ 112,250
Revenue	$ 608,525	$ 112,250

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021	37,124,205
Balance at Dec. 31, 2021	$ 3,713	$ 24,382,195	$ (23,593,069)	$ 792,839
Share-based compensation expense	0	9,145	0	9,145
Issuance of options to settle related party compensation liabilities	$ 0	103,333	0	103,333
Issuance of common shares (in shares)	3,957,757
Issuance of common shares	$ 396	3,957,361	0	3,957,757
Issuance of common shares, participation right and contingent warrant (in shares)	500,000
Issuance of common shares, participation right and contingent warrant	$ 50	499,950	0	500,000
Exercise of warrants (in shares)	217,054
Exercise of warrants	$ 21	(21)	0	0
Net loss	0	0	(3,171,736)	(3,171,736)
Net loss	$ 0	0	(3,171,736)	(3,171,736)
Balance (in shares) at Dec. 31, 2022	41,799,016
Balance at Dec. 31, 2022	$ 4,180	28,951,963	(26,764,805)	2,191,338
Share-based compensation expense	$ 0	21,746	0	21,746
Issuance of common shares (in shares)	2,422,500
Issuance of common shares	$ 244	1,997,256	0	1,997,500
Net loss	0	0	(3,171,436)	(3,171,436)
Net loss	$ 0	0	(3,171,436)	(3,171,436)
Balance (in shares) at Dec. 31, 2023	44,241,516
Balance at Dec. 31, 2023	$ 4,424	$ 30,970,965	$ (29,936,241)	$ 1,039,148

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,171,436)	$ (3,171,736)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	21,746	9,145
Provision for credit losses	160,000	0
Write-off of expired inventory	16,074	0
Gain on settlement of accounts payable	0	(146,438)
Depreciation of property and equipment	15,327	6,827
Amortization of operating lease right of use assets	89,931	67,255
Changes in operating assets and liabilities:
Accounts receivable, net	(318,383)	(92,320)
Inventory, net	14,343	(240,005)
Prepaid expenses and other current assets	21,907	(145,029)
Accounts payable	(3,185)	17,584
Accrued liabilities	65,347	80,086
Operating lease liabilities	(79,452)	(91,494)
Net cash used in operating activities	(3,167,782)	(3,706,126)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(7,244)	(59,992)
Net cash used in investing activities	(7,244)	(59,992)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of common stock, participation right, and contingent warrant	1,997,500	4,457,757
Net cash provided by financing activities	1,997,500	4,457,757
NET INCREASE IN CASH AND CASH EQUIVALENTS	(1,177,527)	691,639
Cash and cash equivalents, beginning of period	2,106,208	1,414,569
Cash and cash equivalents, end of period	928,681	2,106,208
RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
Cash and cash equivalents	2,051,208	1,414,569
Restricted cash	55,000	0
Cash, cash equivalents, and restricted cash, beginning of period	2,106,208	1,414,569
Cash and cash equivalents	928,681	2,051,208
Restricted cash	0	55,000
Cash, cash equivalents, and restricted cash, end of period	928,681	2,106,208
SUPPLEMENTAL INFORMATION
Income taxes	0	0
Interest	4,003	2,268
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Issuance of options to settle accrued compensation liabilities	0	103,333
ROU assets and lease liabilities established at inception of lease	$ 0	$ 426,538

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	9B. None
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 1 - Description of Busines

Note 1 - Description of Business	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Nature of Operations [Text Block]	Note 1 Description of Business Description of Business Nuo Therapeutics, Inc. (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a Delaware corporation organized in 1998 1999, 2000, 2001, 2002 September 2007, 510 April 2010, February 2012, 2014, 2016, 11. May 1, 2019, April 2021, October 2021.

Note 2 - Liquidity and Summary

Note 2 - Liquidity and Summary of Significant Accounting Principles	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2 Liquidity and Summary of Significant Accounting Principles Liquidity Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, and executing licensing arrangements, and to a lesser extent by generating royalties and product revenues. In mid- 2019, April 2021 December 31, 2023, two August December 2023. December 31, 2022, three April, May, September 2022. We have incurred, and continue to incur, recurring losses and negative cash flows. As of December 31, 2023, The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe based on the operating cash requirements and capital expenditures expected for the next twelve 12 not Even assuming we succeed in raising sufficient additional funds in the near future to avoid a cessation of business operations, we require additional capital and will seek to continue financing our operations with external capital for the foreseeable future. Any equity financings may may may not may not Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned, controlled, and inactive subsidiary Aldagen, Inc. (“Aldagen”). All significant inter-company accounts and transactions are eliminated in consolidation. The Company operates its business in one one Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not Credit Concentration We generate accounts receivable from the sale of our products. Specific customer receivable balances in excess of 10% December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Customer A 21 % 0 % Customer B 12 % 0 % Customer C 0 % 19 % Customer D 10 % 17 % Customer E 0 % 16 % Customer F * 14 % Customer G 0 % 12 % * less than 10% Revenue from significant customers exceeding 10% December 31, 2023 December 31, 2022 Year Ended December 31, 2023 Year Ended December 31, 2022 Customer C 0 % 14 % Customer D 12 % 14 % Customer E 0 % 13 % Customer F 0 % 11 % Customer H 10 % 0 % Customer I * 13 % * less than 10% Historically, we used single suppliers for several components of the Aurix product line. We outsource the manufacturing of various product components to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is no one not Cash, Cash Equivalents, and Restricted Cash We consider all highly liquid instruments purchased with an original maturity of three $250,000 December 31, 2023. no December 31, 2023 2022. December 31, 2022, Accounts Receivables, net We generate accounts receivables from the sale of the Aurix products and accounts receivable as of December 31, 2023 three September 30, 2022. We provide for an allowance against receivables for estimated losses that may may not December 31, 2023, December 31, 2023, December 31, 2022, not not Inventory, net Our inventory is produced by third first first 12 two As of December 31, 2023, December 31, 2022, We provide for an allowance against inventory for estimated losses that may December 31, 2023, December 31, 2022, not not Property and Equipment Property and equipment is stated at cost less accumulated depreciation and amortization. Assets are depreciated, using the straight-line method, over their estimated useful life ranging from one six Leases At the inception of a contract, the Company determines if the arrangement is, or contains, a lease. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. The Company has made certain accounting policy elections whereby the Company (i) does not 12 Revenue Recognition The Company analyzes its revenue arrangements to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not not not We recognized initial revenues from commercial sales activities beginning in the three September 30, 2022. Stock-Based Compensation The fair value of employee stock options is measured at the date of grant. Expected volatilities for the 2016 five 2023 2022 Risk free rate 4.37 % 1.65% - 3.47% Weighted average expected years until exercise 5 5 - 6 Expected stock volatility 100 % 100% Dividend yield - - The Company recognizes forfeitures of stock-based awards as they occur. Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. Tax rate changes are reflected in income during the period such changes are enacted. We measure our deferred tax assets and liabilities using the enacted tax rates that we believe will apply in the years in which the temporary differences are expected to be recovered or paid. The Company expects that recent tax law changes contained in the Inflation Reduction Act and CHIPS Act will not A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not not The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no 2023 2022. Basic and Diluted Loss per Share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “treasury method” or “two class method.” Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted- average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible notes using the if-converted method. Because none The following table provides a reconciliation of the numerator and denominators used in the calculation of basic and diluted loss per share for the years ended December 31, 2023 2022: For the year ended December 31, 2023 2022 Net Loss basic and diluted $ (3,171,436 ) $ (3,171,736 ) Weighted average shares outstanding – basic and diluted 42,077,811 40,001,089 Net Loss per Share basic and diluted $ (0.08 ) $ (0.08 ) The following table sets forth the potential dilutive securities excluded from the calculation of diluted loss per share for the years ended December 31, 2023 2022: For the year ended December 31, 2023 2022 Options 3,189,167 3,376,667 Warrants 450,000 450,000 Financing Participation Right and Contingent Warrant 500,000 500,000 Performance Shares 300,000 300,000 4,439,167 4,626,667 Reclassifications Certain amounts as of December 31, 2022 Note 4 Recent Accounting Developments In December 2023, No. 2023 09, 740 December 15, 2024. not We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not

Note 3 - Property and Equipment

Note 3 - Property and Equipment	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 3 Property and Equipment Property and equipment, net consisted of the following: December 31, 2023 December 31, 2022 Medical equipment $ 387,665 $ 387,665 Office/warehouse equipment 43,919 40,026 Warehouse/production equipment 23,317 19,966 454,901 447,657 Less accumulated depreciation (409,819 ) (394,492 ) Property and equipment, net $ 45,082 $ 53,165 Depreciation expense was $15,327 and $6,827, respectively, for the years ended December 31, 2023 December 31, 2022. None December 31, 2023 2022.

Note 4 - Accrued Liabilities

Note 4 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 4 Accrued Liabilities Accrued liabilities consisted of the following: December 31, December 31, 2023 2022 Accrued vacation payable $ 68,538 $ 100,625 Accrued commissions payable 82,400 18,316 Accrued professional fees 19,400 - Other payables 18,284 4,334 Total accrued liabilities $ 188,622 $ 123,275

Note 5 - Stock Purchase Warrant

Note 5 - Stock Purchase Warrants	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Stock Purchase Warrants [Text Block]	Note 5 Stock Purchase Warrants The following schedule reflects outstanding stock purchase warrants as of December 31, 2023 2022: Description December 31, 2023 December 31, 2022 2022 Sales incentive warrants 450,000 450,000 Total 450,000 450,000 During the year ended December 31, 2022, two December 31, 2027 December 31, 2028 2023 2025. 2022 December 31, 2023 zero not Note 6 Equity and Stock-Based Compensation

Note 6 - Equity and Stock-based

Note 6 - Equity and Stock-based Compensation	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	Note 6 Equity and Stock-Based Compensation Under the Company’s Second Amended and Restated Certificate of Incorporation, it has the authority to issue a total of 101,000,000 shares of capital stock, consisting of: (i) 100,000,000 shares of common stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share, which will have such rights, powers and preferences as the Board of Directors of the Company shall determine. 2022 The Company sold 3,957,757 shares of common stock to certain accredited investors pursuant to Securities Purchase Agreements in two April May 2022 April 2022 Pacific Medical Common Stock and Warrant Purchase Agreement In August 2022, Pursuant to the Agreement, Pacific Med purchased 500,000 shares of the Company’s common stock for $500,000. As part of the purchase of common stock, the Company agreed to grant to Pacific Med the right to participate in any future financing by the Company through December 31, 2023 ( not December 31, 2023, January 1, 2024 June 30, 2024, 20 December 31, 2023 ( January 1, 2024 As part of the Agreement and as additional incentive compensation with respect to Pacific Med’s performance under its existing sales and distribution arrangement, the Company also provided to Pacific Med two first 2023 2024. second 2024 2025. December 31, 2027 December 31, 2028. two not December 31, 2023 2022, no 12 June 30, 2024 2025 not December 31, 2023, no December 31, 2023. 2023 The Company sold 2,442,500 shares of common stock to certain accredited investors pursuant to Securities Purchase Agreements in two August December 2023 two 2023 Stock-Based Compensation In July 2016, 2016 “2016 August 2016, first January 1, 2017) six may not November 2016, 2016 March 2022, 2016 June 2022. A summary of stock option activity under the 2016 two December 31, 2023 Stock Options 2016 Omnibus Plan Shares Weighted Average Weighted Outstanding at January 1, 2022 1,355,001 $ 0.52 3.90 Granted 2,021,666 0.73 10.00 Exercised - - - Forfeited or expired - - - Outstanding at January 1, 2023 3,376,667 $ 0.64 6.70 Granted 100,000 0.70 10.00 Exercised - - - Forfeited or expired (287,500 ) (0.75 ) - Outstanding at December 31, 2023 3,189,167 $ 0.64 5.69 Exercisable at December 31, 2023 2,724,861 $ 0.61 5.09 There were 2,021,666 stock options granted under the 2016 December 31, 2022 third third December 31, 2022. During the year ended December 31, 2023, 2016 three The aggregate intrinsic value for outstanding and exercisable options as of December 31, 2023 For the years ended December 31, 2023 2022, December 31, 2023, 2026.

Note 7 - Income Taxes

Note 7 - Income Taxes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 7 Income Taxes Income tax expense (benefit) for the years ended December 31, 2023 2022 Year ended December 31, 2023 2022 Current provision (benefit) Federal $ - $ - State - - - - Deferred provision (benefit) Federal 360,354 396,083 State 20,241 (1,987,646 ) 380,595 (1,591,563 ) Change in valuation allowance (380,595 ) 1,591,563 Consolidated provision (benefit) $ - $ - Significant components of the Company's deferred tax assets and liabilities consisted of the following at December 31, 2023 2022: December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards and credits $ 40,945,364 $ 41,262,032 Property, equipment, intangible assets, and other 297,666 353,310 Stock-based compensation 12,643 20,926 41,255,673 41,636,268 Deferred tax liabilities - - Valuation allowance (41,255,673 ) (41,636,268 ) Net deferred tax assets $ - $ - The following table presents a reconciliation between the U.S. federal statutory income tax rate and the Company's effective tax rate: Year ended December 31, 2023 2022 Federal tax rate (21.0 )% (21.0 )% State tax rate, net of Federal benefit (6.5 )% (6.5 )% Change in valuation allowance (12.0 )% 50.2 % Permanent differences and other 32.6 % (22.7 )% Effective tax rate 6.9 % 0.0 % The Company has Federal net operating loss carry-forwards of approximately $158.1 million as of December 31, 2023. 382 2016 may 2018 20 2028, 2017 not 2017 12 18 not not not

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 8 Commitments and Contingencies In January 2022, December 31, 2024. December 31, 2022 April 2022. In February 2022, March 2027. three March 31, 2022 April 1, 2022; April 1, 2022 10%. Total operating lease costs were approximately $158,000 and $128,000 for the years ended December 31, 2023 December 31, 2022, no 3.0 December 31, 2023. Future undiscounted cash flows under these leases are: 2024 $ 112,833 2025 80,273 2026 82,705 2027 21,283 Total operating lease payments 297,094 Discount factor (41,502 ) Present value of operating lease liabilities 255,592 Current portion of operating lease liabilities (91,387 ) Non-current portion of operating lease liabilities $ 164,205

Note 9 - Subsequent Events

Note 9 - Subsequent Events	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 9 Subsequent Events The Company has evaluated subsequent events through the date the consolidated financial statements were available to be issued. No

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Liquidity, Policy [Policy Text Block]	Liquidity Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, and executing licensing arrangements, and to a lesser extent by generating royalties and product revenues. In mid- 2019, April 2021 December 31, 2023, two August December 2023. December 31, 2022, three April, May, September 2022. We have incurred, and continue to incur, recurring losses and negative cash flows. As of December 31, 2023, The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe based on the operating cash requirements and capital expenditures expected for the next twelve 12 not Even assuming we succeed in raising sufficient additional funds in the near future to avoid a cessation of business operations, we require additional capital and will seek to continue financing our operations with external capital for the foreseeable future. Any equity financings may may may not may not
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned, controlled, and inactive subsidiary Aldagen, Inc. (“Aldagen”). All significant inter-company accounts and transactions are eliminated in consolidation. The Company operates its business in one one
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Concentration We generate accounts receivable from the sale of our products. Specific customer receivable balances in excess of 10% December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Customer A 21 % 0 % Customer B 12 % 0 % Customer C 0 % 19 % Customer D 10 % 17 % Customer E 0 % 16 % Customer F * 14 % Customer G 0 % 12 % * less than 10% Revenue from significant customers exceeding 10% December 31, 2023 December 31, 2022 Year Ended December 31, 2023 Year Ended December 31, 2022 Customer C 0 % 14 % Customer D 12 % 14 % Customer E 0 % 13 % Customer F 0 % 11 % Customer H 10 % 0 % Customer I * 13 % * less than 10% Historically, we used single suppliers for several components of the Aurix product line. We outsource the manufacturing of various product components to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is no one not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents, and Restricted Cash We consider all highly liquid instruments purchased with an original maturity of three $250,000 December 31, 2023. no December 31, 2023 2022. December 31, 2022,
Receivable [Policy Text Block]	Accounts Receivables, net We generate accounts receivables from the sale of the Aurix products and accounts receivable as of December 31, 2023 three September 30, 2022. We provide for an allowance against receivables for estimated losses that may may not December 31, 2023, December 31, 2023, December 31, 2022, not not
Inventory, Policy [Policy Text Block]	Inventory, net Our inventory is produced by third first first 12 two As of December 31, 2023, December 31, 2022, We provide for an allowance against inventory for estimated losses that may December 31, 2023, December 31, 2022, not not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment is stated at cost less accumulated depreciation and amortization. Assets are depreciated, using the straight-line method, over their estimated useful life ranging from one six
Lessee, Leases [Policy Text Block]	Leases At the inception of a contract, the Company determines if the arrangement is, or contains, a lease. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. The Company has made certain accounting policy elections whereby the Company (i) does not 12
Revenue [Policy Text Block]	Revenue Recognition The Company analyzes its revenue arrangements to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not not not We recognized initial revenues from commercial sales activities beginning in the three September 30, 2022.
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The fair value of employee stock options is measured at the date of grant. Expected volatilities for the 2016 five 2023 2022 Risk free rate 4.37 % 1.65% - 3.47% Weighted average expected years until exercise 5 5 - 6 Expected stock volatility 100 % 100% Dividend yield - - The Company recognizes forfeitures of stock-based awards as they occur.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. Tax rate changes are reflected in income during the period such changes are enacted. We measure our deferred tax assets and liabilities using the enacted tax rates that we believe will apply in the years in which the temporary differences are expected to be recovered or paid. The Company expects that recent tax law changes contained in the Inflation Reduction Act and CHIPS Act will not A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not not The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no 2023 2022.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Loss per Share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “treasury method” or “two class method.” Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted- average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible notes using the if-converted method. Because none The following table provides a reconciliation of the numerator and denominators used in the calculation of basic and diluted loss per share for the years ended December 31, 2023 2022: For the year ended December 31, 2023 2022 Net Loss basic and diluted $ (3,171,436 ) $ (3,171,736 ) Weighted average shares outstanding – basic and diluted 42,077,811 40,001,089 Net Loss per Share basic and diluted $ (0.08 ) $ (0.08 ) The following table sets forth the potential dilutive securities excluded from the calculation of diluted loss per share for the years ended December 31, 2023 2022: For the year ended December 31, 2023 2022 Options 3,189,167 3,376,667 Warrants 450,000 450,000 Financing Participation Right and Contingent Warrant 500,000 500,000 Performance Shares 300,000 300,000 4,439,167 4,626,667
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain amounts as of December 31, 2022 Note 4
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments In December 2023, No. 2023 09, 740 December 15, 2024. not We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not

Note 2 - Liquidity and Summar_2

Note 2 - Liquidity and Summary of Significant Accounting Principles (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	December 31, 2023 December 31, 2022 Customer A 21 % 0 % Customer B 12 % 0 % Customer C 0 % 19 % Customer D 10 % 17 % Customer E 0 % 16 % Customer F * 14 % Customer G 0 % 12 % Year Ended December 31, 2023 Year Ended December 31, 2022 Customer C 0 % 14 % Customer D 12 % 14 % Customer E 0 % 13 % Customer F 0 % 11 % Customer H 10 % 0 % Customer I * 13 %
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2023 2022 Risk free rate 4.37 % 1.65% - 3.47% Weighted average expected years until exercise 5 5 - 6 Expected stock volatility 100 % 100% Dividend yield - -
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the year ended December 31, 2023 2022 Net Loss basic and diluted $ (3,171,436 ) $ (3,171,736 ) Weighted average shares outstanding – basic and diluted 42,077,811 40,001,089 Net Loss per Share basic and diluted $ (0.08 ) $ (0.08 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	For the year ended December 31, 2023 2022 Options 3,189,167 3,376,667 Warrants 450,000 450,000 Financing Participation Right and Contingent Warrant 500,000 500,000 Performance Shares 300,000 300,000 4,439,167 4,626,667

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2023 December 31, 2022 Medical equipment $ 387,665 $ 387,665 Office/warehouse equipment 43,919 40,026 Warehouse/production equipment 23,317 19,966 454,901 447,657 Less accumulated depreciation (409,819 ) (394,492 ) Property and equipment, net $ 45,082 $ 53,165

Note 4 - Accrued Liabilities (T

Note 4 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, December 31, 2023 2022 Accrued vacation payable $ 68,538 $ 100,625 Accrued commissions payable 82,400 18,316 Accrued professional fees 19,400 - Other payables 18,284 4,334 Total accrued liabilities $ 188,622 $ 123,275

Note 5 - Stock Purchase Warra_2

Note 5 - Stock Purchase Warrants (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Description December 31, 2023 December 31, 2022 2022 Sales incentive warrants 450,000 450,000 Total 450,000 450,000

Note 6 - Equity and Stock-bas_2

Note 6 - Equity and Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Stock Options 2016 Omnibus Plan Shares Weighted Average Weighted Outstanding at January 1, 2022 1,355,001 $ 0.52 3.90 Granted 2,021,666 0.73 10.00 Exercised - - - Forfeited or expired - - - Outstanding at January 1, 2023 3,376,667 $ 0.64 6.70 Granted 100,000 0.70 10.00 Exercised - - - Forfeited or expired (287,500 ) (0.75 ) - Outstanding at December 31, 2023 3,189,167 $ 0.64 5.69 Exercisable at December 31, 2023 2,724,861 $ 0.61 5.09

Note 7 - Income Taxes (Tables)

Note 7 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year ended December 31, 2023 2022 Current provision (benefit) Federal $ - $ - State - - - - Deferred provision (benefit) Federal 360,354 396,083 State 20,241 (1,987,646 ) 380,595 (1,591,563 ) Change in valuation allowance (380,595 ) 1,591,563 Consolidated provision (benefit) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards and credits $ 40,945,364 $ 41,262,032 Property, equipment, intangible assets, and other 297,666 353,310 Stock-based compensation 12,643 20,926 41,255,673 41,636,268 Deferred tax liabilities - - Valuation allowance (41,255,673 ) (41,636,268 ) Net deferred tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year ended December 31, 2023 2022 Federal tax rate (21.0 )% (21.0 )% State tax rate, net of Federal benefit (6.5 )% (6.5 )% Change in valuation allowance (12.0 )% 50.2 % Permanent differences and other 32.6 % (22.7 )% Effective tax rate 6.9 % 0.0 %

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	2024 $ 112,833 2025 80,273 2026 82,705 2027 21,283 Total operating lease payments 297,094 Discount factor (41,502 ) Present value of operating lease liabilities 255,592 Current portion of operating lease liabilities (91,387 ) Non-current portion of operating lease liabilities $ 164,205

Note 2 - Liquidity and Summar_3

Note 2 - Liquidity and Summary of Significant Accounting Principles (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Proceeds from Issuance of Private Placement		$ 1,997,500	$ 4,457,757
Retained Earnings (Accumulated Deficit)		(29,936,241)	(26,764,805)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents		928,681	2,106,208	$ 1,414,569
Cash, Uninsured Amount		900,000
Accounts Receivable, Credit Loss Expense (Reversal)		160,000	0
Accounts Receivable, Allowance for Credit Loss		32,400	0
Inventory, Finished Goods, Gross		150,000	157,000
Inventory, Raw Materials, Gross		60,000	83,000
Inventory Valuation Reserves		$ 16,000	0
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		1 year
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		6 years
Asset Pledged as Collateral [Member] | Corporate Credit Card [Member]
Restricted Cash			55,000
Private Placement [Member]
Proceeds from Issuance of Private Placement	$ 3,957,757	$ 1,997,500	$ 4,457,757

Note 2 - Liquidity and Summar_4

Note 2 - Liquidity and Summary of Significant Accounting Principles - Summary of Concentration Risk (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Customer A [Member] | Accounts Receivable [Member]
Concentration percentage	21%	0%
Customer C [Member] | Accounts Receivable [Member]
Concentration percentage	0%	19%
Customer C [Member] | Revenue Benchmark [Member]
Concentration percentage	0%	14%
Customer B [Member] | Accounts Receivable [Member]
Concentration percentage	12%	0%
Customer D [Member] | Accounts Receivable [Member]
Concentration percentage	10%	17%
Customer D [Member] | Revenue Benchmark [Member]
Concentration percentage	12%	14%
Customer E [Member] | Accounts Receivable [Member]
Concentration percentage	0%	16%
Customer E [Member] | Revenue Benchmark [Member]
Concentration percentage	0%	13%
Customer F [Member] | Accounts Receivable [Member]
Concentration percentage		14%
Customer F [Member] | Revenue Benchmark [Member]
Concentration percentage	0%	11%
Customer H [Member] | Revenue Benchmark [Member]
Concentration percentage	10%	0%
Customer I [Member] | Revenue Benchmark [Member]
Concentration percentage		13%
Customer G [Member] | Accounts Receivable [Member]
Concentration percentage	0%	12%

Note 2 - Liquidity and Summar_5

Note 2 - Liquidity and Summary of Significant Accounting Principles - Summary Stock Option Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Risk free rate		1.65%
Weighted average expected years until exercise (Year)		5 years
Expected stock volatility		100%
Dividend yield		0%
Minimum [Member]
Risk free rate	4.37%
Weighted average expected years until exercise (Year)	5 years
Expected stock volatility	100%
Maximum [Member]
Risk free rate		3.47%
Weighted average expected years until exercise (Year)		6 years
Dividend yield	0%

Note 2 - Liquidity and Summar_6

Note 2 - Liquidity and Summary of Significant Accounting Principles - Earnings (Loss) Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Net Loss – basic and diluted	$ (3,171,436)	$ (3,171,736)
Weighted average shares outstanding – basic and diluted (in shares)	42,077,811	40,001,089
Net loss per share – basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)

Note 2 - Liquidity and Summar_7

Note 2 - Liquidity and Summary of Significant Accounting Principles - Anti-dilutive Securities Excluded From the Computation of Diluted Earnings (Loss) Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Anti-dilutive securities (in shares)	4,439,167	4,626,667
Share-Based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	3,189,167	3,376,667
Warrant [Member]
Anti-dilutive securities (in shares)	450,000	450,000
Contingent Warrants Upon Future Financing Events [Member]
Anti-dilutive securities (in shares)	500,000	500,000
Performance Shares [Member]
Anti-dilutive securities (in shares)	300,000	300,000

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Depreciation	$ 15,327	$ 6,827

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment - Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, plant, and equipment, gross	$ 454,901	$ 447,657
Less accumulated depreciation	(409,819)	(394,492)
Property and equipment, net	45,082	53,165
Medical Equipment [Member]
Property, plant, and equipment, gross	387,665	387,665
Office Warehouse Equipment [Member]
Property, plant, and equipment, gross	43,919	40,026
Warehouse and Production Equipment [Member]
Property, plant, and equipment, gross	$ 23,317	$ 19,966

Note 4 - Accrued Liabilities -

Note 4 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Accrued vacation payable	$ 68,538	$ 100,625
Accrued commissions payable	82,400	18,316
Accrued professional fees	19,400	0
Other payables	18,284	4,334
Total accrued liabilities	$ 188,622	$ 123,275

Note 5 - Stock Purchase Warra_3

Note 5 - Stock Purchase Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
The 2022 Sales Incentive Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1
The 2022 Sales Incentive Warrants [Member] | Distribution Partner [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.5
Class of Warrant or Right, Outstanding, Aggregate Intrinsic Value	$ 0
Contingent Warrants Upon Future Financing Events [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	500,000

Note 5 - Stock Purchase Warra_4

Note 5 - Stock Purchase Warrants - Outstanding Stock Purchase Warrants (Details) - shares	Dec. 31, 2023	Dec. 31, 2022
Outstanding warrants (in shares)	450,000	450,000
The 2022 Sales Incentive Warrants [Member]
Outstanding warrants (in shares)	450,000	450,000

Note 6 - Equity and Stock-bas_3

Note 6 - Equity and Stock-based Compensation (Details Textual) - USD ($)		1 Months Ended	12 Months Ended
	Aug. 24, 2022	Apr. 30, 2022	Dec. 31, 2025	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Jan. 01, 2024	Mar. 31, 2022	Aug. 04, 2016
Authorized Shares, Common and Preferred (in shares)					101,000,000
Common Stock, Shares Authorized (in shares)					100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized (in shares)					1,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.0001
Proceeds from Issuance of Private Placement					$ 1,997,500	$ 4,457,757
Stock Issued During Period, Value, New Issues					1,997,500	3,957,757
Share-Based Payment Arrangement, Expense					21,746	9,145
Issuance of Options to Settle Accrued Compensation Liabilities					0	103,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value					178,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount					74,000
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, New Issues					$ 1,997,256	$ 3,957,361
The 2016 Omnibus Plan [Member]
Evergreen Provision, Increase in Number of Shares Authorized Calculation, Percentage Amount of Prior Year's Reserved Shares									6%
Evergreen Provision, Maximum Limit of Increase to Authorized Shares (in shares)									1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)								4,250,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					100,000	2,021,666
The 2016 Omnibus Plan [Member] | Immediately Vested Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)						450,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value						$ 6,430
The 2016 Omnibus Plan [Member] | Incentive Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)					100,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value					$ 53,500
The 2016 Omnibus Plan [Member] | Additional Paid-in Capital [Member]
Issuance of Options to Settle Accrued Compensation Liabilities						$ 103,333
The 2016 Omnibus Plan [Member] | Senior Management and Board of Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						206,666
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value						$ 3,000
The 2016 Omnibus Plan [Member] | Management, Board of Directors, Service Provider [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						450,000
The 2016 Omnibus Plan [Member] | Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						1,355,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)						3 years
The 2016 Omnibus Plan [Member] | Consultant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						10,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)						1 year
Participation Rights [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	500,000
Contingent Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	500,000
Class of Warrant or Right, Purchase Price of Warrants or Rights (in dollars per share)	$ 2
Contingent Warrant [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 0.56
First Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1
Warrants and Rights Outstanding	$ 434,000
Second Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.5
Warrants and Rights Outstanding	$ 345,000
First and Second Compensatory Performance-based Stock Purchase Warrants [Member]
Share-Based Payment Arrangement, Expense					0	$ 0
Pacific Med [Member]
Stock Issued During Period, Shares, New Issues (in shares)	500,000
Stock Issued During Period, Value, New Issues	$ 500,000
Share-Based Payment Arrangement, Expense					0
Common Stock, Capital Shares Agreed for Future Issuance Upon Milestone Achievement, Fair Value	$ 615,000
Pacific Med [Member] | Forecast [Member]
Sales and Distribution Agreement, Milestone Achievement, Minimum Revenue to be Achieved			$ 12,500,000	$ 4,500,000
Pacific Med [Member] | Maximum [Member]
Common Stock, Capital Shares Agreed for Future Issuance Upon Milestone Achievement (in shares)	300,000
Principal Shareholder, Members of the Board of Directors, and a Member of Senior Management [Member]
Proceeds from Issuance of Private Placement		$ 940,400			$ 760,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		3,957,757			2,442,500
Proceeds from Issuance of Private Placement		$ 3,957,757			$ 1,997,500	$ 4,457,757

Note 6 - Equity and Stock-bas_4

Note 6 - Equity and Stock-based Compensation - Stock Option Activity (Details) - The 2016 Omnibus Plan [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Shares outstanding (in shares)	3,376,667	1,355,001
Shares outstanding, weighted-average exercise price (in dollars per share)	$ 0.64	$ 0.52
Shares outstanding, weighted-average remaining contractual term (Year)	5 years 8 months 8 days	6 years 8 months 12 days	3 years 10 months 24 days
Shares granted (in shares)	100,000	2,021,666
Shares granted, weighted-average exercise price (in dollars per share)	$ 0.7	$ 0.73
Shares granted, weighted-average remaining contractual term (Year)	10 years		10 years
Shares exercised (in shares)	0	0
Shares exercised, weighted-average exercise price (in dollars per share)	$ 0	$ 0
Shares forfeited or expired (in shares)	(287,500)	0
Shares forfeited or expired, weighted-average exercise price (in dollars per share)	$ (0.75)	$ 0
Shares outstanding (in shares)	3,189,167	3,376,667	1,355,001
Shares outstanding, weighted-average exercise price (in dollars per share)	$ 0.64	$ 0.64	$ 0.52
Shares exercisable (in shares)	2,724,861
Shares exercisable, weighted-average exercise price (in dollars per share)	$ 0.61
Shares exercisable, weighted-average remaining contractual term (Year)	5 years 1 month 2 days

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) $ in Thousands	Dec. 31, 2023 USD ($)
Operating Loss Carryforwards	$ 158,100
Liability for Uncertainty in Income Taxes, Current	$ 0

Note 7 - Income Taxes - Income

Note 7 - Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal	$ 0	$ 0
State	0	0
Federal	360,354	396,083
State	20,241	(1,987,646)
Deferred Income Tax Expense (Benefit)	380,595	(1,591,563)
Change in valuation allowance	(380,595)	1,591,563
Provision (benefit) for income taxes	$ 0	$ 0

Note 7 - Income Taxes - Deferre

Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating loss carryforwards and credits	$ 40,945,364	$ 41,262,032
Property, equipment, intangible assets, and other	297,666	353,310
Stock-based compensation	12,643	20,926
Deferred Tax Assets, Gross	41,255,673	41,636,268
Deferred tax liabilities	0	0
Valuation allowance	(41,255,673)	(41,636,268)
Net deferred tax assets	$ 0	$ 0

Note 7 - Income Taxes - Incom_2

Note 7 - Income Taxes - Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal tax rate	(21.00%)	(21.00%)
State tax rate, net of Federal benefit	(6.50%)	(6.50%)
Change in valuation allowance	(12.00%)	50.20%
Permanent differences and other	32.60%	(22.70%)
Effective tax rate	6.90%	0%

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Apr. 01, 2022	Jan. 31, 2022
Operating Lease, Right-of-Use Asset	$ 269,354	$ 359,284	$ 337,226	$ 89,312
Operating Lease, Weighted Average Discount Rate, Percent			10%	10%
Operating Lease, Expense	$ 158,000	$ 128,000
Operating Lease, Weighted Average Remaining Lease Term (Year)	3 years

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Future Undiscounted Cash Flows (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
2024	$ 112,833
2025	80,273
2026	82,705
2027	21,283
Total operating lease payments	297,094
Discount factor	(41,502)
Present value of operating lease liabilities	255,592
Current portion of operating lease liabilities	(91,387)	$ (79,453)
Non-current portion of operating lease liabilities	$ 164,205	$ 255,592